Gelofusine affects the quality control performance of QuickVue point-of-care human chorionic gonadotropin test devices.
To characterize the influence of Gelofusine (succinylated gelatin) on the performance of point-of-care testing (POCT) for human chorionic gonadotropin (hCG) devices. Three brands of urine and urine/serum hCG POCT devices were verified. Succinylated gelatin affected the performance of the control band in the QuickVue hCG POCT devices. Alternative devices were not affected. The hCG test performance is not influenced. Gelofusine affects specifically the quality control performance of the QuickVue hCG POCT devices.